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Abstract
Many patients with chronic obstructive pulmonary disease (COPD) die each year as those with lung cancer but current
guidelines make few recommendations on the care for the most severe patients i.e. those with Global Initiative for Chronic
Obstructive Lung Disease (GOLD) stages III and IV with chronic respiratory failure.
Only smoking cessation and long term oxygen therapy (LTOT) improve survival in COPD. Although non invasive positive
pressure ventilation (NPPV) may have an adjunctive role in the management of chronic respiratory insufficiency there is little
evidence for its use in the routine management of stable hypercapnic COPD patients. At difference, several prospective,
randomised, controlled studies, systematic reviews and meta-analyses show good level of evidence for clinical efficacy of
NPPV in the treatment of acute on chronic respiratory failure due to acute exacerbations of COPD. NPPV is also alternative to
invasive ventilation for symptom relief in end stage COPD.
Surgical interventions for end stage COPD like bullectomy, different modalities of lung volume reduction surgery and lung
transplantation are likely to be of value to only a small percentage of patients. Nevertheless, there are specific indications,
which, when added to pulmonary rehabilitation will further advance exercise capacity and quality of life.
As in other chronic diseases when severity of disease increases along the natural history, therapy aimed to prolong life
becomes less and less important in comparison to palliative therapy aimed to relieve symptoms. The most effective
treatments for dyspnoea are bronchodilators, although also opiates may improve dyspnoea. Supplemental oxygen reduce
exertional breathlessness and improve exercise tolerance in hypoxaemic COPD patients. There are difficulties in treating
with antidepressant the frail and elderly COPD patients.
Good clinical care can prevent or alleviate suffering by assessing symptoms and providing psychological and social support
to the patients and their families.
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Introduction
Many patients with chronic obstructive pul-
monary disease (COPD) die each year as those with
lung cancer, and health decline occurs over a sub-
stantial period before that. Until recently, little
attention was paid to the healthcare needs of the
most severe COPD patients. Indeed current guide-
lines make few recommendations on the care for
the most severe patients i.e. those with Global Ini-
tiative for Chronic Obstructive Lung Disease
(GOLD) stages III and IV with chronic respiratory
failure [1, 2].
COPD affects 6% of the general population and
is a leading cause of morbidity and mortality world-
wide, GOLD stages III–IV accounting for 4.5 and
0.4% respectively in males and 2.2 and 0.3% in
females [3]. Age-adjusted mortality continues to in-
crease at difference with mortality from other le-
ading causes of death, including cardiovascular
disease and cancer [2].
Exacerbations. Patients admitted to Intensive
Care Unit (ICU) with an acute exacerbation of
COPD (AECOPD) have a median survival of 2 years,
and 50% of patients are readmitted to the hospital
within 6 months [4]. In these patients hypercap-
Pneumonologia i Alergologia Polska 2009, tom 77, nr 2, strony 173–179
174 www.pneumonologia.viamedica.pl
treated. Hypoxaemic COPD patients, in LTOT, may
show reduced QOL, decreased ability to cope with
ADL, cognitive function, and depression [15].
As greater numbers of patients survive inten-
sive care it is becoming increasingly evident that
QOL after critical illness may be compromised.
COPD patients surviving acute on chronic respi-
ratory failure and requiring mechanical ventilation
suffer worsened perceived health status and cogniti-
ve function than stable COPD patients on LTOT who
have never previously required ICU/RICU admission.
After discharge the health and cognitive status may
improve to levels similar to those of stable COPD
patients on LTOT [16]. In daily practice, the presen-
ce of psychological complaints or mental disorders
in patients with COPD is often regarded as a compli-
cation caused by the physical complaints. As a re-
sult, they are regularly overlooked, often remain un-
diagnosed and are rarely treated [15].
Treatment perspectives for survival
Drug therapy. Only smoking cessation and
LTOT improve survival in COPD [17]. Recent stu-
dies of inhaled corticosteroid therapy for managing
stable COPD have yielded conflicting results regar-
ding survival and risk of adverse events [18]. Stu-
dies have shown an association between inhaled
corticosteroids and a reduction in mortality and re-
hospitalisation, with some caveats, an effect may-
be associated with anti-inflammatory action [19,
20]. A large, randomised, controlled clinical trial
has tested this hypothesis prospectively [21] and
results seems to show an advantage in survival by
using inhaled combination of beta2 long acting
agonists with steroids. The real effectiveness of
inhaled steroids in very severe patients has not
been assessed yet. Furthermore oral corticostero-
ids as maintenance treatment in patients with end-
-stage respiratory disease are an independent risk
factor for death, and should be avoided in most
cases [22]. The effects of inhaled anticholinergics
are even more discussed [23, 24]. Beta-blockers are
often withheld from patients with COPD because
of fear of pulmonary worsening. However, cardio-
selective b-blockers are demonstrated to be safe and
beneficial in patients with COPD and are benefi-
cial in the reduction of mortality in patients with
COPD undergoing vascular surgery, with an inten-
sified dosage being most effective [25].
Oxygen
Long-Term Oxygen Therapy is the main treat-
ment for patients with chronic respiratory insuf-
nia at discharge is related to inspiratory work, re-
spiratory muscle strength, and breathing pattern
[5]. The mortality rate after an AECOPD is high,
especially for older patients with chronic respira-
tory failure in whom the symptom burden in the
last six months of life is significant [6]. The 6-year
mortality of patients with AECOPD requiring ICU
admission is substantial (at 6 yrs, around 15% are
alive) and is mainly influenced by pre-ICU admis-
sion quality of life (QoL) [7].
Systemic effects. COPD affects many organ
systems in addition to the lungs [8]. Poor exercise
capacity and peripheral muscle dysfunction may
be linked by the presence of systemic inflammation.
Patients with COPD have higher levels of C-reacti-
ve protein independent of coexisting cardiac or non-
-cardiac risks [9]. The risk of atherosclerosis, cardio-
vascular disease and mortality is further increased
in COPD individuals who smoke [10, 11]. Patients
with severe COPD become less mobile and reduce
their activities of daily living (ADL). In a survey of
patients with severe COPD (Medical Research Co-
uncil dyspnoea grade 5) treated with LTOT, 50% did
not leave the house and 78% were breathless wal-
king around at home and performing ADL [12].
Nutrition. Survival studies have consistently
shown significantly greater mortality rates in un-
derweight and normal-weight than in overweight
and obese COPD patients. Malnutrition is a com-
mon and underrecognized problem in hospitalised
patients. Indeed hospitalization is frequently as-
sociated with negative energy balance and further
deterioration in nutritional status. A survey of ad-
missions to a general hospital reported a prevalen-
ce of malnutrition of 27% to 46% across various
hospital specialities. In particular nutritional de-
pletion is a common problem in COPD patients. It
is caused, to a large extent, by an imbalance be-
tween low-energy intake and high-energy require-
ments leading to muscle wasting and dysfunction [13].
A compromised nutrition is associated with a poor
prognosis in stable COPD patients with and with-
out respiratory failure [14].
Health status and psychological effects. Al-
though the underlying pathology is initially con-
fined to the lungs, the associated psychological
responses to COPD contribute greatly to the resul-
ting morbidity. The ability to function in ADL, as
well as the QOL of a patient with COPD, may be
further complicated by psychological complaints
or even a concurrent mental disorder. Although the
physical illness itself probably contributes to the
occurrence and severity of the psychological com-
plaints, this does not mean that these complaints
will be resolved once the respiratory complaints are
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ficiency due to advanced COPD. LTOT administe-
red continuously (> 18 hours per day) to hypoxa-
emic COPD patients increases survival [26]. It is
generally implemented according to international
recommendations [27]. The prescription of LTOT
should always include the source of supplemen-
tal oxygen (gas or liquid), method of delivery, du-
ration of use, and flow rate at rest, during exerci-
se, and during sleep. Oxygen therapy during exer-
cise improves exercise endurance and dyspnoea
[28]. A randomised study, failed to find an advan-
tage in QoL of ambulatory oxygen over placebo in
COPD patients who did not meet criteria for mor-
tality reduction with LTOT, thus not supporting
the general “off label” application of this treatment
for patients not meeting recognised criteria for
LTOT [29].
Non invasive positive pressure ventilation
Non invasive positive pressure ventilation
(NPPV), delivered by nasal or face mask, avoids the
risks associated with invasive ventilation. It assists
ventilation by improving inspiratory flow rate,
correcting hypoventilation, resting respiratory
muscles and resetting the central respiratory drive
[30]. The benefits of NPPV in stable patients are
equivocal, with little evidence to support NPPV in
addition to LTOT in the treatment of chronic hy-
percapnic COPD. One trial published as an abstract
[31], indicated that there was no overall survival
benefit from NPPV plus LTOT, despite a slight
improvement in survival for patients over 65 years.
An Italian 2-year multi-centre trial showed that
NPPV plus LTOT improved daytime PaCO2, dysp-
noea and QoL, although survival was similar to the
control (LTOT alone) group [32]. In a systematic
review of short and long-term NPPV in stable hy-
percapnic COPD patients, 15 studies met the in-
clusion criteria: 6 randomised trials and 9 non ran-
domised controlled trials, with no improvements
identified in the former. Hyperinflation and dia-
phragmatic work of breathing were reduced in
a subset of patients [33]. Therefore, although NPPV
may have an adjunctive role in the management
of chronic respiratory insufficiency there is little
evidence for its use in the routine management of
stable hypercapnic COPD patients [34].
NPPV in acute exacerbations of COPD. Acu-
te exacerbations of COPD are important events in
the natural course of disease leading to deteriora-
ting in lung function and in QoL and, when asso-
ciated with acute ventilatory failure, to severe
short-and long-term prognosis. Frequency of
AECOPD increases with disease severity, as repre-
sented by airflow obstruction, although the rela-
tionship between AECOPD frequency and severi-
ty of airflow obstruction is not particularly close
and new evidence indicates a possible role for
extrapulmonary factors in the genesis of exacerba-
tion. Indeed the most severe COPD patients, espe-
cially those with several comorbidities are prone
to more severe exacerbations and are likely to need
hospital admission, especially in the winter mon-
ths when respiratory viral infections are common
[35, 36]. A stepwise drug therapy is recommended
for both home and hospital management. Hospital
management includes proper assessment of seve-
rity, diagnosis of the cause, controlled O2 therapy
and/or mechanical ventilation with an early non-
-invasive approach as first line of intervention [37].
A very severe life threatening episode requires di-
rect admission into the ICU. Several prospective,
randomised, controlled studies, systematic reviews
and meta-analyses show good level of evidence for
clinical efficacy of NPPV in the treatment of acute
on chronic respiratory failure due to AECOPD.
Compared to standard medical therapy alone,
NPPV improved survival, reduced the need for
endotracheal intubation and the rate of complica-
tions, and shortened the hospital and ICU length
of stay [38].
NPPV in palliative care. NPPV is alternative
to invasive ventilation for symptom relief in end
stage COPD [39] and a recent European survey of
respiratory intermediate care units has reported
a frequency of use and its role in almost a third of
the patients among patients with poor life expec-
tancy [40]. The Society of Critical Care Medicine
has recently charged a Task Force with developing
an approach for considering use of NPPV for pa-
tients who choose to forego endotracheal intuba-
tion. In acute respiratory failure it can be classi-
fied as follows: 1) NPPV as life support with no
preset limitations on life-sustaining treatments,
2) NPPV as life support when patients and families
have decided to forego endotracheal intubation,
and 3) NPPV as a palliative measure when patients
and families have chosen to forego all life support
and receive only comfort measures. The goals of
using NPPV and the parameters for success and
failure, should be discussed by experienced per-
sonnel, in appropriate healthcare settings [41].
Rehabilitation
Patients with COPD demonstrate reduced le-
vels of spontaneous physical activity compared
with healthy controls. Furthermore, patients recei-
ving LTOT have an even lower level of domestic
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activity compared with that of those not on LTOT
but with COPD of similar severity [42]. Pulmona-
ry rehabilitation is an evidence based, multidisci-
plinary intervention comprising exercise training,
education and psychological support and aimed at
reducing disability and improving QoL [43]. In
a multi-centre study of 1047 COPD patients pulmo-
nary rehabilitation improved outcomes in patients
both with and without chronic respiratory failure
[44]. Also COPD patients in the ICU benefit from
pulmonary rehabilitation, and guidelines have
been developed [45–47]. In the frame of pulmona-
ry rehabilitation, neuromuscular transcutaneous
electrical stimulation (NMES) of the lower limb
muscles increased muscular oxidative capacities.
Small controlled studies with this technique in
severe and even bed-bound COPD patients have
been reported [48].
Surgery
Surgical interventions for end stage COPD are
likely to be of value to only a small percentage of
patients. Nevertheless, there are specific indica-
tions, which, when added to pulmonary rehabilita-
tion will further advance exercise capacity and QoL.
Bullectomy is an established surgical proce-
dure for bullous emphysema. In carefully selected
patients, this procedure is effective in reducing
dyspnoea and improving lung function. In consi-
dering the possible benefit of surgery it is impor-
tant to estimate the effect of the bulla on the lung
and the function of the remaining (non-bullous) lung.
Some investigators have recommended that the bul-
la must occupy 50% or more of the hemithorax and
produce definite displacement of the adjacent lung
before surgery can be recommended [49].
Lung Volume Reduction Surgery (LVRS) is
a surgical procedure in which parts of the lung are
removed, to reduce hyperinflation, making respi-
ratory muscles more effective by improving their
mechanical efficiency, and improving overall gas
exchange. Nevertheless LVRS in an unselected po-
pulation with severe COPD had no effect on morta-
lity, and in patients with FEV1 and DLCO levels
< 20% predicted, there was an increased risk of
death whereas in selected patients with upper lobe
disease and a low exercise capacity, LVRS impro-
ved mortality, exercise capacity, and QoL [50–53].
Given the increased risk of such procedures
among patients with the most severe disease, al-
ternatives have been studied. These include bron-
choscopic LVRS and endobronchial valve place-
ment which show improvements in exercise capa-
city and dynamic hyperinflation have been repor-
ted. Given the cost-effectiveness of LVRS, it is still
considered a palliative surgical procedure for pa-
tients with advanced COPD [54]. Experimental stu-
dies of biological lung volume reduction using bio-
logical reagents to remodel and shrink damaged
regions of the lung, are encouraging for patients
with advanced heterogeneous emphysema [55]. All
these techniques are promising, but have to date
not been firmly studied.
Lung Transplantation (LTx) (single or double)
is an option for a more limited number of patients,
with highly impaired lung function, hypercapnia
and secondary pulmonary hypertension. Despite
the progress over the past 25 years, short and long-
-term outcomes of lung recipients are not as good
as those for other solid organs [56, 57]. Pulmonary
function improves, but exercise capacity may still
be limited due to a peripheral muscle dysfunction
[58]. Pulmonary rehabilitation further improves
exercise and QoL, after LTx [59]. According to the
International Society for Heart and Lung Trans-
plantation’s registry the survival for emphysema
on 1 year is 85% and on three years is 68%, signi-
ficant complications still impairing survival [60].
Supportive therapy
As in other chronic diseases when severity of
disease increases along the natural history, thera-
py aimed to prolong life becomes less and less im-
portant in comparison to palliative therapy aimed
to relieve symptoms [61].
Dyspnoea
Dyspnoea is the most important complaint in
severe COPD. It is mainly evoked by exercise but
may also be present at rest, especially during
AECOPD of end-stage disease and can be incapa-
citating. Several strategies, may be considered and
have been recently described elsewhere [62].
Drug therapy. The most effective treatments
for dyspnoea are bronchodilators, although also
a non pharmacological approach like LVRS may also
improve dyspnoea. In end-stage disease one option
may be also to reduce the ventilatory demand by
decreasing the central drive with opiates. These
have been shown to decrease minute ventilation
at rest and during submaximal exercise thus redu-
cing the sensation of breathing and its associated
anxiety. Therapeutic doses of opioids induce col-
lateral effects such as peripheral vasodilation and
baroreceptor response inhibition which need to be
carefully evaluated. Despite safety concerns, the-
se drugs do have place in the management of pa-
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tients in the terminal phase of their disease [63].
No consistent improvement in dyspnoea over pla-
cebo has been shown with anxiolitics. Nonetheless
the American Thoracic Society statement recom-
mends a trial of anxiolitic therapy on an individu-
al basis [64]. Despite recent findings [65] do not
support a beneficial effect from nebulised furose-
mide in patients with cancer related breathlessness,
relief of exertional dyspnoea after single-dose fu-
rosemide inhalation in COPD is multifactorial but
improvements in dynamic ventilatory mechanics
are contributory in some individuals [66].
Breathed mixtures. Hypoxia contributes to
dyspnoea by stimulating minute ventilation. Sup-
plemental oxygen during exercise reduces exertio-
nal breathlessness and improves exercise toleran-
ce in hypoxaemic COPD patients by: reduced hy-
poxic stimulation of the carotid bodies, pulmona-
ry vasodilation, increase in arterial oxygen tension.
Also reduced hyperinflation plays an important
role in the oxygen-related relief of dyspnoea [67].
Reducing the gas density with heliox has also been
shown to reduce ventilation and improve exercise
capacity. The reduction in ventilation improves
expiratory flow and reduces dynamic hyperinfla-
tion, thereby decreasing the operational lung vo-
lume and reducing the work of breathing [68].
Psychological consequences
and cognitive status
Severe COPD patients experience a greater
prevalence of depression compared with patients
with mild or moderate disease. a possible causal
association between depression and AECOPD and
hospitalisation. Interventional trials appear to be
warranted to evaluate the effectiveness of antide-
pressants and psychotherapies on reducing exacer-
bations [69]. There are difficulties in treating with
antidepressant the frail and elderly COPD patients.
Furthermore clinicians, care-givers and patients
should be careful in prescription and assumption
of benzodiazephines due to the risk of precipita-
ting a severe episode of hypercapnia [15]. Pulmo-
nary rehabilitation improves depression and anxie-
ty in some COPD patients, although all pulmona-
ry rehabilitation programmes include psychologi-
cal therapy for those patients with high levels of
depression and anxiety symptoms [70].
Conclusion
Good clinical care can prevent or alleviate
suffering by assessing symptoms and providing
psychological and social support to the patients
and their families. There are recommendations
based on systematic evidence review. The recom-
mendations are:
In patients with serious illness at the end of
life, clinicians should regularly assess patients for
pain, dyspnoea, and depression, manage with the-
rapies of proven effectiveness for pain, dyspnoea
(including opioids and oxygen) and depression.
They should ensure that advance care planning,
including completion of advance directives, (in
countries where available and/or legal) occurs for
all patients with serious illness. Providing patients
and their families with information about treat-
ment options and anticipating possible future ne-
eds are crucial steps to appropriately tailor the
management of the respiratory issues. These pa-
tients must be involved in the decision-making
process on treatment escalation, such as endotra-
cheal intubation, tracheotomy and eventually the
option of palliative care [71–74]. As expected the-
re are differences in attitudes toward end-of life
decisions in different European countries. A survey
promoted by the European Respiratory Society [40]
has shown that in European respiratory interme-
diate care and high dependency units, an end of-
life decision is taken for 30% of the patients ad-
mitted. The most common practices were withhol-
ding treatment, the use of non-invasive ventilation
[39] as a ceiling therapy and provision of a do-not-
resuscitate/do-not-intubate order, the latter occur-
ring significantly more frequently in North com-
pared with South Europe. Patients, when compe-
tent, and their families are often involved, together
with nurses, in reaching these key decisions [40].
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